Adriano Lazzarin
About
In The Last Decade
Adriano Lazzarin
603 papers receiving 19.9k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Infectious Diseases 12.2k
- Virology 10.9k
- Epidemiology 6.2k
- Emergency Medicine 3.4k
- Immunology 2.8k
Countries citing papers authored by Adriano Lazzarin
This map shows the geographic impact of Adriano Lazzarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriano Lazzarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriano Lazzarin more than expected).
Fields of papers citing papers by Adriano Lazzarin
This network shows the impact of papers produced by Adriano Lazzarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriano Lazzarin. The network helps show where Adriano Lazzarin may publish in the future.
Co-authorship network of co-authors of Adriano Lazzarin
This figure shows the co-authorship network connecting the top 25 collaborators of Adriano Lazzarin. A scholar is included among the top collaborators of Adriano Lazzarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriano Lazzarin. Adriano Lazzarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic. | 12 |
| 3 | 9 | |
| 4 | 37 | |
| 5 | CD4+ Cell Restoration at 48 Weeks in the Maraviroc (MVC) Treatment-Naive (TN) MERIT Trial | 1 |
| 6 | Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy. | 6 |
| 7 | 15 | |
| 8 | The introduction of the fusion inhibitors in the HAART-regimens. | 3 |
| 9 | Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a. | 9 |
| 10 | Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. | 10 |
| 11 | Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. | 16 |
| 12 | 238 | |
| 13 | 91 | |
| 14 | 95 | |
| 15 | Selective enrichment of CD30-expressing cells within the blast region of lymphocytes from patients with primary HIV infection (PHI). | 3 |
| 16 | 4 | |
| 17 | Phenotype of intramyocardial leukocytic infiltrates in acquired immunodeficiency syndrome (AIDS): a postmortem immunohistochemical study in 34 consecutive cases. | 10 |
| 18 | 34 | |
| 19 | Proposta per la diagnosi, stadiazione e terapia del Kaposi epidemico. | 1 |
| 20 | Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. | 59 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.